Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389944 | 0.91 | DRD2 (0.46) | DRD2DRD3DRD4LMNAMAPT | |
| SCHEMBL3387755 | 0.90 | DRD2 (0.43) | DRD2DRD3DRD4LMNAMAPT | |
| SCHEMBL6788728 | 0.88 | DRD2 (0.41) | DRD2DRD3DRD4LMNAMAPT | |
| SCHEMBL3388370 | 0.88 | DRD2 (0.41) | DRD2DRD3DRD4LMNAMEN1 | |
| SCHEMBL6342504 | 0.83 | DRD2 (0.59) | DRD2DRD3DRD4LMNAMAPT | |
| SCHEMBL3390894 | 0.79 | MAPT (0.36) | DRD2DRD3DRD4LMNAMAPT | |
| SCHEMBL6620561 | 0.78 | MAPT (0.34) | DRD2DRD3DRD4MAPTHTT | |
| SCHEMBL6593135 | 0.78 | DRD2 (0.42) | DRD2DRD3DRD4 | |
| SCHEMBL5222458 | 0.77 | MAPT (0.37) | DRD2DRD3DRD4MAPTGAA | |
| SCHEMBL6334727 | 0.76 | DRD2 (0.61) | DRD2DRD3DRD4LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453805-B1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | claimed |
| EP-1453805-B1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-1453805-B1 | 4-PIPERIDINYL ALKYLAMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-6864266-B2 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-03-08 | — | — | US | disclosed |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | BROTHERTON-PLEISS CHRISTINE E (US) | 2004-05-13 | — | — | US | disclosed |
| US-6627644-B2 | Muscarinic receptor antagonists and parasympathetic nervous system. The physiological actions of Acetylcholine are mediated by activation of either nicotinic or muscarinic receptors | SYNTEX (U.S.A.) LLC | 2003-09-30 | — | — | US | disclosed |
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) LLC, NAME CHANGED TO ROCHE PALO ALTO LLC | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM1, CHRM3, CHRM2 | DRD2 50/4885DRD3 56/4885DRD4 149/4885 |
| US-20040092554-A1 | 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists | CHRM1, CHRM3, CHRM2 | DRD2 50/4885DRD3 56/4885DRD4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.